Both stocks trade below nine times forward earnings, but payout safety differs amid Pfizer’s elevated ratio and acquisition costs.
Pfizer and Verizon Communications present dividend yields of 7.1% and 6.7%, respectively, appealing to income-focused investors. Both stocks trade at valuations under nine times projected earnings, positioning them as value opportunities in their sectors.
Verizon’s payout ratio stands at 67%, a sustainable level for dividend stability. Pfizer’s ratio exceeds 100%, though earnings are depressed by acquisition-related expenses and non-cash charges, complicating its dividend safety assessment.
The stocks operate in distinct industries, with Pfizer in pharmaceuticals and Verizon in telecommunications, yet both maintain long-term track records of dividend payments.